Cargando…
Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC
BACKGROUND: To establish the feasibility of the dosimetric compliance criteria of the RTOG 1308 trial through testing against Intensity Modulation Radiation Therapy (IMRT) and Passive Scattering Proton Therapy (PSPT) plans. METHODS: Twenty-six lung IMRT and 26 proton PSPT plans were included in the...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855766/ https://www.ncbi.nlm.nih.gov/pubmed/27142674 http://dx.doi.org/10.1186/s13014-016-0640-8 |
_version_ | 1782430409330524160 |
---|---|
author | Giaddui, Tawfik Chen, Wenzhou Yu, Jialu Lin, Liyong Simone, Charles B. Yuan, Lulin Gong, Yutao U. T. Wu, Q. Jackie Mohan, Radhe Zhang, Xiaodong Bluett, Jaques B. Gillin, Michael Moore, Kevin O’Meara, Elizabeth Presley, Jennifer Bradley, Jeffrey D. Liao, Zhongxing Galvin, James Xiao, Ying |
author_facet | Giaddui, Tawfik Chen, Wenzhou Yu, Jialu Lin, Liyong Simone, Charles B. Yuan, Lulin Gong, Yutao U. T. Wu, Q. Jackie Mohan, Radhe Zhang, Xiaodong Bluett, Jaques B. Gillin, Michael Moore, Kevin O’Meara, Elizabeth Presley, Jennifer Bradley, Jeffrey D. Liao, Zhongxing Galvin, James Xiao, Ying |
author_sort | Giaddui, Tawfik |
collection | PubMed |
description | BACKGROUND: To establish the feasibility of the dosimetric compliance criteria of the RTOG 1308 trial through testing against Intensity Modulation Radiation Therapy (IMRT) and Passive Scattering Proton Therapy (PSPT) plans. METHODS: Twenty-six lung IMRT and 26 proton PSPT plans were included in the study. Dose Volume Histograms (DVHs) for targets and normal structures were analyzed. The quality of IMRT plans was assessed using a knowledge-based engineering tool. RESULTS: Most of the RTOG 1308 dosimetric criteria were achieved. The deviation unacceptable rates were less than 10 % for most criteria; however, a deviation unacceptable rate of more than 20 % was computed for the planning target volume minimum dose compliance criterion. Dose parameters for the target volume were very close for the IMRT and PSPT plans. However, the PSPT plans led to lower dose values for normal structures. The dose parameters in which PSPT plans resulted in lower values than IMRT plans were: lung V(5Gy) (%) (34.4 in PSPT and 47.2 in IMRT); maximum spinal cord dose (31.7 Gy in PSPT and 43.5 Gy in IMRT); heart V(5Gy) (%) (19 in PSPT and 47 in IMRT); heart V(30Gy) (%) (11 in PSPT and 19 in IMRT); heart V(45Gy) (%) (7.8 in PSPT and 12.1 in IMRT); heart V(50%) (Gy) (7.1 in PSPT and 9.8 in IMRT) and mean heart dose (7.7 Gy in PSPT and 14.9 Gy in IMRT). CONCLUSIONS: The revised RTOG 1308 dosimetric compliance criteria are feasible and achievable. |
format | Online Article Text |
id | pubmed-4855766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48557662016-05-05 Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC Giaddui, Tawfik Chen, Wenzhou Yu, Jialu Lin, Liyong Simone, Charles B. Yuan, Lulin Gong, Yutao U. T. Wu, Q. Jackie Mohan, Radhe Zhang, Xiaodong Bluett, Jaques B. Gillin, Michael Moore, Kevin O’Meara, Elizabeth Presley, Jennifer Bradley, Jeffrey D. Liao, Zhongxing Galvin, James Xiao, Ying Radiat Oncol Research BACKGROUND: To establish the feasibility of the dosimetric compliance criteria of the RTOG 1308 trial through testing against Intensity Modulation Radiation Therapy (IMRT) and Passive Scattering Proton Therapy (PSPT) plans. METHODS: Twenty-six lung IMRT and 26 proton PSPT plans were included in the study. Dose Volume Histograms (DVHs) for targets and normal structures were analyzed. The quality of IMRT plans was assessed using a knowledge-based engineering tool. RESULTS: Most of the RTOG 1308 dosimetric criteria were achieved. The deviation unacceptable rates were less than 10 % for most criteria; however, a deviation unacceptable rate of more than 20 % was computed for the planning target volume minimum dose compliance criterion. Dose parameters for the target volume were very close for the IMRT and PSPT plans. However, the PSPT plans led to lower dose values for normal structures. The dose parameters in which PSPT plans resulted in lower values than IMRT plans were: lung V(5Gy) (%) (34.4 in PSPT and 47.2 in IMRT); maximum spinal cord dose (31.7 Gy in PSPT and 43.5 Gy in IMRT); heart V(5Gy) (%) (19 in PSPT and 47 in IMRT); heart V(30Gy) (%) (11 in PSPT and 19 in IMRT); heart V(45Gy) (%) (7.8 in PSPT and 12.1 in IMRT); heart V(50%) (Gy) (7.1 in PSPT and 9.8 in IMRT) and mean heart dose (7.7 Gy in PSPT and 14.9 Gy in IMRT). CONCLUSIONS: The revised RTOG 1308 dosimetric compliance criteria are feasible and achievable. BioMed Central 2016-05-04 /pmc/articles/PMC4855766/ /pubmed/27142674 http://dx.doi.org/10.1186/s13014-016-0640-8 Text en © Giaddui et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Giaddui, Tawfik Chen, Wenzhou Yu, Jialu Lin, Liyong Simone, Charles B. Yuan, Lulin Gong, Yutao U. T. Wu, Q. Jackie Mohan, Radhe Zhang, Xiaodong Bluett, Jaques B. Gillin, Michael Moore, Kevin O’Meara, Elizabeth Presley, Jennifer Bradley, Jeffrey D. Liao, Zhongxing Galvin, James Xiao, Ying Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC |
title | Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC |
title_full | Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC |
title_fullStr | Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC |
title_full_unstemmed | Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC |
title_short | Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC |
title_sort | establishing the feasibility of the dosimetric compliance criteria of rtog 1308: phase iii randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage ii-iiib nsclc |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855766/ https://www.ncbi.nlm.nih.gov/pubmed/27142674 http://dx.doi.org/10.1186/s13014-016-0640-8 |
work_keys_str_mv | AT giadduitawfik establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT chenwenzhou establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT yujialu establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT linliyong establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT simonecharlesb establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT yuanlulin establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT gongyutaout establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT wuqjackie establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT mohanradhe establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT zhangxiaodong establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT bluettjaquesb establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT gillinmichael establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT moorekevin establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT omearaelizabeth establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT presleyjennifer establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT bradleyjeffreyd establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT liaozhongxing establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT galvinjames establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc AT xiaoying establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc |